Loading…
AbbVie Inc. is projected to rise to $310.99 by 2027, a +21% move from its current price of $256.91. ABBV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 29 | $253.31 | $257.03 | $260.80 | +0.05% |
| Jul 30 | $251.90 | $257.14 | $262.50 | +0.09% |
| Jul 31 | $250.85 | $257.26 | $263.84 | +0.14% |
| Aug 1 | $249.98 | $257.38 | $264.99 | +0.18% |
| Aug 2 | $249.24 | $257.49 | $266.03 | +0.23% |
| Aug 3 | $248.57 | $257.61 | $266.98 | +0.27% |
| Aug 4 | $247.98 | $257.73 | $267.86 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $247.98 | $257.73 | $267.86 | +0.32% |
| Week 2 | $244.82 | $258.55 | $273.05 | +0.64% |
| Week 3 | $242.61 | $259.37 | $277.29 | +0.96% |
| Week 4 | $240.88 | $260.20 | $281.07 | +1.28% |
| Week 5 | $239.46 | $261.03 | $284.54 | +1.60% |
| Week 6 | $238.25 | $261.86 | $287.81 | +1.93% |
| Week 7 | $237.21 | $262.69 | $290.92 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbbVie Inc. is a healthcare company that engages in the research-based biopharmaceutical business, with activities in research and development, manufacturing, commercialization, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow’s feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson’s disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. (ABBV) is a Healthcare stock ranked 19 with a market cap of $453.91B. The current price is $256.91. The stock sits in a large-cap pharmaceutical space with a broad portfolio across autoimmune, cancer, eye care, dermatology, and other therapeutic areas.
The near-term outlook shows a neutral stance, while the longer horizon implies meaningful upside in the years ahead. The 2026 forecast for the stock lists an average price of $256.91, a min of $197.38, and a max of $353.92 with ROI 0 and a NEUTRAL sentiment. As the years progress, the forecast shifts to a bullish stance, with the 2030 average of $497.55 and the 2050 average of $2,847.95, and with a max price forecast up to $4,655.41 and ROI up to 1008.5%.
This points to robust long-term upside despite the near-term ambiguity.
A major floor 23.2% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
Price is pressing into resistance (1.6% away) — a breakout level to watch.
A major ceiling 12.6% above — clearing it would confirm fresh momentum.
Key ABBV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABBV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $255.32 | Buy | $255.30 | Buy |
| MA 10 | $252.24 | Buy | $253.49 | Buy |
| MA 20 | $252.70 | Buy | $249.33 | Buy |
| MA 50 | $233.25 | Buy | $237.57 | Buy |
| MA 100 | $222.23 | Buy | $229.08 | Buy |
| MA 200 | $224.00 | Buy | $221.95 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.05 | Neutral |
| Stoch RSI (14) | 65.35 | Neutral |
| CCI (20) | 89.72 | Neutral |
| Williams %R (14) | -0.08 | Info |
| MACD (12,26,9) | -0.56 | Sell |
| ROC (12) | 1.65 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 99.92 | Sell |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | 13.21 | Buy |
| Ultimate (7,14,28) | 70.75 | Sell |
| Momentum (10) | 8.83 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 257.18 | Sell |
| ADX (14) | 27.22 | Buy |
| ATR (14) | 2.96 | Info |
The 30-day technical picture is bullish in sentiment. RSI14 is 60, indicating a neutral to modestly bullish momentum, with the price trading above both the SMA50 and the SMA200 (SMA50 is $233.25 and SMA200 is $224.00). Support is seen at $216.49 and resistance at $261.07, framing a constructive short-term setup.
The 30-day price range runs from $233.37 to $282.83, reflecting active movement within a relatively wide band. The current price of $256.91 sits above the short- and intermediate-term moving averages, reinforcing the positive tone but with notable volatility implied by an annualized volatility of 30%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $197.38 | $256.91 | $353.92 | 0% | Neutral | |
| $254.95 | $310.99 | $396.45 | +21% | Bullish | |
| $289.26 | $359.56 | $470.92 | +40% | Bullish | |
| $328.51 | $414.69 | $554.79 | +61% | Bullish | |
| $388.87 | $497.55 | $677.71 | +94% | Bullish | |
| $469.44 | $607.99 | $841.31 | +137% | Bullish | |
| $497.99 | $652.29 | $915.50 | +154% | Bullish | |
| $531.08 | $702.97 | $999.46 | +174% | Bullish | |
| $585.02 | $782.09 | $1,125.28 | +204% | Bullish | |
| $609.62 | $822.71 | $1,196.94 | +220% | Bullish | |
| $942.46 | $1,326.67 | $2,022.91 | +416% | Bullish | |
| $1,886.31 | $2,847.95 | $4,655.41 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $197.38 | $256.91 | $301.55 | +0.00% |
| August 2026 | $227.81 | $265.81 | $316.21 | +3.46% |
| September 2026 | $228.23 | $267.78 | $321.45 | +0.74% |
| October 2026 | $229.33 | $270.28 | $326.81 | +0.93% |
| November 2026 | $237.52 | $280.98 | $341.76 | +3.96% |
| December 2026 | $243.82 | $289.41 | $353.92 | +3.00% |
Click any year to see its month-by-month ABBV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABBV to range from $197.38 to $353.92 through 2026. The $256.91 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABBV price prediction for 2027 points to an average of $310.99 (low $254.95, high $396.45) — a potential gain of +21% on today's $256.91. Buyers look set to stay in control over this stretch.
In 2028, ABBV is projected to trade between $289.26 and $470.92, averaging $359.56 — a potential gain of +40% from today's $256.91. That is up +16% on the projected 2027 average. Momentum favours further upside here.
AbbVie Inc.'s 2029 outlook centres on $414.69, within a $328.51 to $554.79 range. That is up +15% on the projected 2028 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ABBV could reach as high as $677.71, with a base case around $497.55 and support toward $388.87 — roughly +94% from $256.91. Momentum favours further upside here.
Expect ABBV to range from $469.44 to $841.31 through 2031. The $607.99 average target implies a +137% move from current prices. That is up +22% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABBV price prediction for 2032 points to an average of $652.29 (low $497.99, high $915.50) — a potential gain of +154% on today's $256.91. Momentum favours further upside here.
In 2033, ABBV is projected to trade between $531.08 and $999.46, averaging $702.97 — a potential gain of +174% from today's $256.91. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
AbbVie Inc.'s 2034 outlook centres on $782.09, within a $585.02 to $1,125.28 range. That is up +11% on the projected 2033 average. That marks a +204% change versus current levels. Momentum favours further upside here.
By 2035, ABBV could reach as high as $1,196.94, with a base case around $822.71 and support toward $609.62 — roughly +220% from $256.91. Buyers look set to stay in control over this stretch.
Expect ABBV to range from $942.46 to $2,022.91 through 2040. The $1,326.67 average target implies a +416% move from current prices. That is up +61% on the projected 2035 average. Momentum favours further upside here.
The ABBV price prediction for 2050 points to an average of $2,847.95 (low $1,886.31, high $4,655.41) — a potential gain of +10.1x on today's $256.91. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABBV today (≈ 3.892414 ABBV) could be worth
$11,085.4
+$10,085.4 (+1009%) by 2050 · US Dollar
Based on the average projected ABBV price of $2,847.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABBVwould be worth at today's price.
$1,000 invested in ABBV on Jul 28, 2025 (≈ 5.304477 ABBV) would be worth
$1,362.77
+$362.77 (+36.3%) today · 1.36× · US Dollar
Based on a ABBV entry price of $188.52 vs. today's $256.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $253.38 | $1,013.93 | +1.4% |
| 1 month ago | $253.35 | $1,014.05 | +1.4% |
| 3 months ago | $197.69 | $1,299.56 | +30.0% |
| 6 months ago | $218.67 | $1,174.88 | +17.5% |
| 1 year ago | $188.52 | $1,362.77 | +36.3% |
| All time (5.0y) ago | $118.87 | $2,161.27 | +116.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABBV forecast.
Our base-case forecast reaches $510.00 around 2031.
Implied market cap at $510.00: $901.06B
The multi-year forecast shows a strong bullish trajectory after 2026. The 2027 average is $310.99 with a max of $396.45 and a 21.1% ROI, followed by even larger gains in subsequent years. By 2030, the average forecast rises to $497.55 with a max of $677.71 and a 93.7% ROI, signaling meaningful upside.
The path continues to 2040, where the average is $1,326.67 and the max is $2,022.91 with a 416.4% ROI, underscoring substantial long-term upside. By 2050, the average reaches $2,847.95 and the max $4,655.41, with a 1008.5% ROI, all labeled as BULLISH. These figures suggest a persistent bullish long-term outlook, albeit with the usual uncertainty around future price.
Investors should regard these as estimates, not guarantees, and monitor risk factors and market conditions as they evolve.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $497.55, with a min of $388.87 and a max of $677.71; ROI 93.7%; sentiment BULLISH.
The long-term forecast shows bullish sentiment from 2027 onward, with rising averages to $2,847.95 by 2050 and a max of $4,655.41; ROI to 1008.5% by 2050.
The 30-day range is $233.37 to $282.83.
The 2040 forecast lists a min of $942.46, an average of $1,326.67, and a max of $2,022.91; ROI 416.4%; sentiment BULLISH.
By 2050, the forecast shows an average of $2,847.95 and a max of $4,655.41, with a min of $1,886.31; ROI 1008.5%; sentiment BULLISH.
AbbVie Inc. Community Discussion
0Share your AbbVie Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.